Pfizer Inc., Bayer AG and Novartis AG are dominating the Argentina Menopause Drugs in 2022

Argentina Menopause Drugs Market is expected to grow with the CAGR of 4.6% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @

Argentina menopause drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Argentina menopause drugs market are introducing wide range of product portfolio. This helped companies to maximize the sales of menopause drugs and product portfolio.

For instance,

  • In October, Pfizer Inc. announced that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis . This helped the company to grow its product portfolio.

Argentina Menopause Drugs MarketPfizer Inc.

Pfizer Inc. was founded in 1849 and has it base headquarters in New York, the U.S. The company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The business segments are medicine safety, product list, product contacts, for professionals, patient assistance programs and distributors.  The market focused category is product list.

For instance,

  • In December ,Pfizer Inc. announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis. This product helped the company to enhance the revenue of the company

The company has presence in South America, North America, Asia-Pacific, and Europe. The subsidiaries are Hospira (the U.S.), Pfizer Japan Inc (Japan), Pfizer UK (the U.K.), Array BioPharma (the U.S.) and Parke-Davis (the U.S.).

Bayer AG

Bayer AG was found in 1863 and is headquartered in Leverkusen, Germany. The company is focused towards creating value for their customers, stockholders and employees while strengthening the company's earning power. The business segments are crop science, pharmaceuticals, consumer health. The market focused segment is pharmaceuticals.

The product categories are crop science, pharmaceuticals, consumer health. The market focused category is pharmaceuticals.

For instance,

  • In August 2021, Bayer AG had performed the phase 3 clinical trials research and development (R&D) program OASIS with elinzanetant. The elinzanetant is a non-hormonal therapy, which is being investigated for treatment of vasomotor symptoms during menopause. The clinical trials being performed, would address the unmet medical need in women’s health, since majority of women are not receiving treatment for their menopausal symptoms. It would result in availability of elinzanetant in hospitals and clinics in Argentina

The subsidiaries are Argentina SRL (Argentina), Bayer CropScience Holdings Pty Ltd (Australia), and Bayer CropScience Ltd. (Bangladesh) among others. The global presence is Africa, Asia, Australia, & New Zealand, Europe, Latin America, and Middle East and North America.

Novartis AG

Novartis AG was founded in 1996 and is headquartered in Basel-Stadt, Switzerland. The company is focused in reimaging medicine to improve and extend people's lives and enhancing their growth in healthcare. The business segments are patients and caregivers, healthcare professionals, research & development, ESG. The market focused segment are healthcare professionals. The company offers range of product categories such as estradiol, paroxetine, anti-depressants, gabapentin. The market focused category is estradiol, paroxetine, anti-depressants, and gabapentin.

The company has global presence in South America, North America, Asia-Pacific, and Europe.  The subsidiaries are Sandoz (Switzerland), Hexal AG (Germany), Novartis Pharma K.K. (Japan), Advanced Accelerator Applications (France) and Novartis Gene Therapies (the U.S.) among others.